STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today ...
New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...
In this case study, a patient who had Duchenne muscular dystrophy (DMD) and received high-dose transgene therapy to upregulate cortical dystrophin subsequently developed acute respiratory distress ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results